Skip to main content
Quest Diagnostics

Estimating Risk of Severe COVID-19 Based on Initial Biomarker Assessment

Joint Statistical Meetings

JSM 2023

Toronto, Ontario, Canada, Aug 5-10, 2023

Poster presentation: Estimating Risk of Severe COVID-19 Based on Initial Biomarker Assessment

Authors: Bi C, Kroll MH, Salm AE, Szymanski J, Goldstein Y, Wolgast LR, Rosenblatt G, Fox A, Kapoor H

Specialty: Infectious Disease, COVID-19

Related content

Conference Presentation
Prediction of Severe COVID-19 Based on Routine Biomarker Assessment
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Audio Podcast
Commitment to Employee Health: A Blueprint for Wellness
Publication
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.